CA2193396A1 - Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition - Google Patents

Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition

Info

Publication number
CA2193396A1
CA2193396A1 CA002193396A CA2193396A CA2193396A1 CA 2193396 A1 CA2193396 A1 CA 2193396A1 CA 002193396 A CA002193396 A CA 002193396A CA 2193396 A CA2193396 A CA 2193396A CA 2193396 A1 CA2193396 A1 CA 2193396A1
Authority
CA
Canada
Prior art keywords
beta
chained
straight
contain
lupeol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002193396A
Other languages
English (en)
Inventor
Kurt Berg
Sýren Brýgger Christensen
Carsten Boye-Knudsen
Chen Ming
Beth Simonsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2193396A1 publication Critical patent/CA2193396A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Une composition pharmaceutique pour prévenir et/ou traiter les infections virales et éventuellement des inflammations, contient un ou plusieurs dérivés du .beta.-lupéol, éventuellement en combinaison avec un composé libérant un ion ammonium et/ou en combinaison avec un ou plusieurs mono-, oligo- ou polysaccharides mono- ou polysulfatés, ou des analogues et/ou des dérivés de ceux-ci. La composition pharmaceutique peut se présenter sous la forme de chewing-gums, de pastilles pharmaceutiques, de comprimés à mâcher, de comprimés sublinguaux, de gouttes, de tablettes, de gels, de collutoires, de solutions, de formulations mucoadhésives et de dépôts. L'invention concerne également une méthode pour prévenir et pour traiter des infections virales et éventuellement des inflammations, par l'administration par voie orale de la composition pharmaceutique de l'invention.
CA002193396A 1994-06-20 1995-06-20 Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition Abandoned CA2193396A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK72294 1994-06-20
DK92694 1994-08-09

Publications (1)

Publication Number Publication Date
CA2193396A1 true CA2193396A1 (fr) 1995-12-28

Family

ID=26064526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002193396A Abandoned CA2193396A1 (fr) 1994-06-20 1995-06-20 Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition

Country Status (10)

Country Link
EP (1) EP0762876A1 (fr)
JP (1) JPH10504279A (fr)
KR (1) KR970703759A (fr)
CN (1) CN1158566A (fr)
AU (1) AU689603B2 (fr)
CA (1) CA2193396A1 (fr)
EE (1) EE9600190A (fr)
FI (1) FI965114A0 (fr)
NO (1) NO965468L (fr)
WO (1) WO1995035103A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4995597A (en) * 1996-10-23 1998-05-15 Vertex Pharmaceuticals Incorporated Methods of using sucrose octasulfate to treat or prevent enveloped virus infection
US6251371B1 (en) * 1997-01-09 2001-06-26 Bifodan A/S Treatment of skin or mucosa inflammation by topical treatment with preparation containing dichlorobenzyl alcohol
WO1998032443A1 (fr) * 1997-01-24 1998-07-30 Marigen S.A. Ultramicro-emulsions de concentres spontanement dispersibles renfermant des esters de triterpenes pentacycliques a activite antitumorale, antivirale et antiparasitaire
US6482857B1 (en) 1998-07-17 2002-11-19 The University Of Texas Southwestern Medical Center Compositions which contain triterpenes for regulating hair growth
US6124362A (en) * 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
ES2272689T3 (es) * 2001-01-12 2007-05-01 Bsp Pharma A/S Dihidro-triterpenos en el tratamiento de infecciones virales, enfermedad cardiovascular, inflamacion, hipersensibilidad o dolor.
FR2822821B1 (fr) * 2001-04-03 2004-05-07 Pharmascience Lab Extrait de coques de graines de lupin contenant du lupeol, en particulier extrait riche en lupeol et son procede de preparation
CN104761460B (zh) * 2015-03-26 2017-06-20 苏州沪云肿瘤研究中心股份有限公司 蓝萼甲素衍生物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983637A (en) * 1988-06-24 1991-01-08 Stephen Herman Method for treating viral infection of HIV

Also Published As

Publication number Publication date
CN1158566A (zh) 1997-09-03
AU689603B2 (en) 1998-04-02
WO1995035103A1 (fr) 1995-12-28
NO965468D0 (no) 1996-12-19
EP0762876A1 (fr) 1997-03-19
FI965114A (fi) 1996-12-19
KR970703759A (ko) 1997-08-09
AU2734095A (en) 1996-01-15
EE9600190A (et) 1997-06-16
NO965468L (no) 1997-02-19
FI965114A0 (fi) 1996-12-19
JPH10504279A (ja) 1998-04-28

Similar Documents

Publication Publication Date Title
EP1007077B1 (fr) Glutathione destines au traitement de l'infection grippale
EP0532595B1 (fr) Utilisation pharmacologique de certains derives de cystine
KR950702834A (ko) 글루칸 제제(novel glucan preparation)
EP1556023B1 (fr) Compositions nutritionnelles ou therapeutiques
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
EP0495116B1 (fr) Agent anti-vih
CZ382799A3 (cs) Použití hyaluronátu zinku proti peptickým vředům
CA2193396A1 (fr) Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition
GB2427824A (en) Treatment of proliferative or viral conditions
DK155672B (da) Analogifremgangsmaade til fremstilling af aminosyrederivater eller fysiologisk acceptable salte eller optisk aktive isomerer deraf
CA2544432A1 (fr) Composition pharmaceutique stable comportant le facteur stimulant les colonies de granulocytes
KR20050104346A (ko) 포진 바이러스 감염의 치료법 또는 증상 예방법
US6077838A (en) Method of treating hangover
JP4580479B2 (ja) 抗ｈｉｖ感染症剤
NZ205587A (en) Composition comprising undecylenic acid for treating herpes simplex i
US4436732A (en) Medicated compound for treating diseases infected by virus of the herpes group
US5869446A (en) Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections
DE69714821T2 (de) Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen
JPH0623108B2 (ja) 腫瘍形成抑制用組成物
JP2535633B2 (ja) エチル ６―ブロモ―５―オキシ―４―ジメチルアミノメチル―１―メチル―２―フェニルチオメチルインド―ル―３―カルボキシレ―ト ハイドロクロライド モノハイドレ―ト，その調製方法、それを含む抗ウイルス性，インタ―フェロン―誘導及び免疫変調効果を持つ薬剤の調製
EP0753309A2 (fr) Composition de lactoferrine (ou de protéines analogues) et de méthanesulfonate de désferrioxamine (ou d'autres chélateurs d'ions métalliques) pour la thérapie de maladies infectieuses virales
CA1209043A (fr) Methode et produit de traitement de l'herpes simplex
KR100585242B1 (ko) 인플루엔자감염증치료용화합물및조성물
KR20010108040A (ko) 항-ｈｉｖ 감염증제 및 ｈｉｖ 감염증의 치료 방법
US4230725A (en) Antiviral agent

Legal Events

Date Code Title Description
FZDE Dead